Does OLAPARIB Cause Myelosuppression? 359 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 359 reports of Myelosuppression have been filed in association with OLAPARIB (Lynparza). This represents 2.0% of all adverse event reports for OLAPARIB.
359
Reports of Myelosuppression with OLAPARIB
2.0%
of all OLAPARIB reports
17
Deaths
110
Hospitalizations
How Dangerous Is Myelosuppression From OLAPARIB?
Of the 359 reports, 17 (4.7%) resulted in death, 110 (30.6%) required hospitalization, and 27 (7.5%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 359 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which OLAPARIB Alternatives Have Lower Myelosuppression Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL